Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

22.64 +0.11 (+0.47%)
Delayed Quote Updated: 2:58 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Arcus Biosciences Shares Are Down Today: What's Going On? ↗
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering. 
Via Benzinga
News headline image
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
From Arcus Biosciences
Via Business Wire
News headline image
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts ↗
 
Via Benzinga
News headline image
Unveiling 5 Analyst Insights On Arcus Biosciences ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium
From Arcus Biosciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Where Arcus Biosciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
From Arcus Biosciences
Via Business Wire
News headline image
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.